Hope Rugo, MD, Oncology, San Francisco, CA, UCSF Medical Center

HopeS.RugoMD

Oncology San Francisco, CA

Hematologic Oncology

Clinical Professor of Medicine, UCSF

Dr. Rugo is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Rugo's full profile

Already have an account?

Education & Training

  • UCSF
    UCSFFELLOWSHIP
  • UCSF
    UCSFRESIDENCY
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaMEDICAL_SCHOOL

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1986 - 2022
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2009-2014
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanc... 
    2019 ASCO Annual Meeting - 6/1/2019
  • SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast ca... 
    2019 ASCO Annual Meeting - 6/1/2019
  • The association of early toxicity and outcomes for patients treated with abemaciclib. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
  • Join now to see all

Authored Content

  • Palbociclib plus Endocrine Therapy in Older Women with HR+/HER2– Advanced Breast Cancer: A Pooled Analysis of Randomised PALOMA Clinical StudiesAugust 2018
  • The New World of Biosimilars in Oncology: Translation of Data to the ClinicApril 2018

Press Mentions

  • Keytruda Approved for Triple-Negative Breast Cancer
    Keytruda Approved for Triple-Negative Breast CancerNovember 17, 2020 12:57
  • FDA Approves Merck’s KEYTRUDA® (Pembrolizumab) in Combination with Chemotherapy for Patients with Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)
    FDA Approves Merck’s KEYTRUDA® (Pembrolizumab) in Combination with Chemotherapy for Patients with Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)November 14, 2020 16:02
  • Tucatinib Triplet Takes up Residence in Third-Line Metastatic HER2+ Breast Cancer
    Tucatinib Triplet Takes up Residence in Third-Line Metastatic HER2+ Breast CancerNovember 07, 2020 15:37
  • Join now to see all

Professional Memberships

Hospital Affiliations